Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Flores Contreras, Lucia ^a   Sandoval Rodríguez, Ana S ^a   Mena Enriquez, Mayra G ^a   Lucano Landeros, Silvia ^a   Arellano Olivera, Inmaculada ^a,b   Álvarez Álvarez, Arnulfo ^a   Sanchez Parada, M G ^a   Armendáriz Borunda, Juan ^a,c  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c INNOVARE   (Mexico)

Author keywords

Cannabinoid receptor 1; Cannabinoid receptor 2; Chronic hepatitis C; Cytokines; Liver fibrosis; Necroinflammation; Pirfenidone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANNABINOID 2 RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; CANNABINOID 1 RECEPTOR; CNR1 PROTEIN, HUMAN; CNR2 PROTEIN, HUMAN; CYTOKINE; IL6 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE; TGFB1 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CB1 GENE; CB2 GENE; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; FEMALE; GASTRITIS; GENE EXPRESSION REGULATION; HEADACHE; HEPATITIS C; HISTOLOGICAL ACTIVITY INDEX; HUMAN; HUMAN TISSUE; IL6 GENE; INFLAMMATION; INSOMNIA; LIVER BIOPSY; LIVER FIBROSIS; MALE; NAUSEA; NECROINFLAMMATION; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SCORING SYSTEM; SOMNOLENCE; STEATOSIS; TGF BETA1 GENE; TNF ALPHA GENE; VIRAL GENETICS; VIRUS LOAD; VOMITING; WEAKNESS; AGED; CLINICAL TRIAL; COHORT ANALYSIS; FATTY LIVER; GENE EXPRESSION; GENETICS; HEPATITIS C, CHRONIC; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYTOKINES; FATTY LIVER; FEMALE; GENE EXPRESSION; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-6; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PYRIDONES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904774216     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-131     Document Type: Article

References (43)

1. Friedman SL. Liver fibrosis: from bench to bedside. J Hepatol 2003, 38:38-53.
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 7:13(17):2436-2441.
3. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000, 132:296-305. 10.7326/0003-4819-132-4-200002150-00008, 10681285.
4. Memom MI, Memom MA. Hepatitis C: an epidemiological review. J Viral Hepat 2002, 9:84-100. 10.1046/j.1365-2893.2002.00329.x, 11876790.
5. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364(25):2417-2428. 10.1056/NEJMoa1013086, 21696308.
6. Foote BS, Spooner LM, Belliveau PP. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother 2011, 45(9):1085-1093. 10.1345/aph.1P744, 21828346.
7. Wang F, Wen T, Chen XY, Wu H. Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxixity in rats. Inflamm Res 2008, 57:183-188. 10.1007/s00011-007-7153-8, 18344059.
8. Tsuchiya H, Kaibori M, Yanagida H, Yokoigawa N, Kwon AH, Okuma T, Kamiyama Y. Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats. J Hepatol 2004, 40:94-101.
9. Garcia-Benavides L, Hernandez I, Sandoval A, Salazar A, Garcia J, Vera J, Grijalva G, Muriel P, Margolin S, Armendariz-Borunda J. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002, 37:797-805. 10.1016/S0168-8278(02)00272-6, 12445421.
10. Di Sario A, Bendia E, Macarri G, Candelaresi C, Taffetani S, Marzioni M, Omenetti A, De Minicis S, Trozzi L, Benedetti A. The anti-fibrotic effects of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha 1(l), TIMP-1 and MMP2. DigLiverDis 2004, 36(11):744-751.
11. Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, Rincon AR, Lucano S, Sandoval AS, Salazar A, Berumen J, Covarrubias A, Arechiga G, Garcia L. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006, 55(11):1663-1665. 10.1136/gut.2006.107136, 1860119, 17047115.
12. McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004, 53:318-321. 10.1136/gut.2003.026393, 1773949, 14960506.
13. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002, 97:2408-2414. 10.1111/j.1572-0241.2002.05995.x, 12358265.
14. Hézode S, Roudot-Thoraval F, Nguyen S. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005, 42:63-71.
15. Zampino R, Marrone A, Restivo L, Guerra B, Sellitto A, Rinaldi L. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013, 5(10):528-540. 3812455, 24179612.
16. Mallat A, Lotersztajn S. Endocannabinoids and Liver Disease I: Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol 2008, 294:9-12.
17. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology 2011, 53:346-355. 10.1002/hep.24077, 3073545, 21254182.
18. Siegmund SV, Schwabe RF. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008, 294(2):357-362.
19. Julien B, Grenard P, Texeira-Clerc F, van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the Liver. Gastroenterology 2005, 128:742-755. 10.1053/j.gastro.2004.12.050, 15765409.
20. Parfieniuk A, Flisiak R. Role of cannabinoides in chronic liver diseases. World J Gastroenterol 2008, 28:14(40):6190-6114.
21. Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, Jimenez W. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol ExpTher 2008, 324(2):475-483.
22. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011, 22(6):1144-1151. 10.1681/ASN.2010101049, 3103734, 21511828.
23. King Talmadge E, Bradford Williamson Z, Castro-Bernardini S, Fagan Elizabeth A, Glaspole I, Glassberg Marilyn K, Gorina E, Hopkins Peter M, Kardatzke D, Lancaster L, Lederer David J, Nathan Steven D, Pereira Carlos A, Sahn Steven A, Sussman R, Swigris Jeffrey J, Noble Paul W. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092. 10.1056/NEJMoa1402582, 24836312.
24. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Grootes J, Gudat F, Denk H, Desmet V, Korb G, MacSeweeni RNM, Phillips MJ, Portmannl BG, Paulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22(6):696-699. 10.1016/0168-8278(95)80226-6, 7560864.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
26. De Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003, 2(1):5-11.
27. World Health Organization. [http://www.who.int/mediacentre/factsheets/fs311/en/].
28. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464. 10.1053/jhep.2001.22172, 11172350.
29. Texeira-Clerc F, Julien B, Grenard P, Nhieu JT, Deveaux V, Li L, Serriere-Lanneau V, Ledent C, Mallat A, Loterstajn S. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006, 12(6):671-676. 10.1038/nm1421, 16715087.
30. Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, Armendariz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 2010, 1:3-16.
31. Gancedo M, Ruiz-Corro L, Salazar-Montes A, Rincon AR, Armendáriz-Borunda J. Pirfenidone in capsular contracture after mammary implantation. Aesth Plast Surg 2008, 32:32-40.
32. Veras-Castillo ER, Cardenas-Camarena L, Lyra-Gonzalez I, Muñoz-Valle JF, Lucano-Landeros S, Guerrero-Santos J, Ganzalez-Ulloa B, Mercado-Barajas JL, Sanchez-Parada MG, Azabache-Wenneceslao R, Armendariz-Borunda J. Controlled clínical trial with pirfenidone in the treatment of breast capsular contracture. Ann Plast Surg 2011, In press.
33. Salazar-Montes A, Ruiz-Corro L, Lopez-Reyes A, Castrejon-Gomez E, Armendariz-Borunda J. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 2008, 24(595):69-77.
34. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002, 20(1-3):177-185.
35. Lyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 291(1):367-373.
36. Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 1998, 20(12):685-695. 10.1016/S0192-0561(98)00042-3, 9877280.
37. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter?. Gut 2006, 55:123-130. 10.1136/gut.2005.069757, 1856395, 16344578.
38. Fartoux L, Chazouillères O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005, 41:82-87. 10.1002/hep.20519, 15690484.
39. Toyoda M, Kitaoka A, Machida K, Nishinakagawa T, Yada R, Kohjima M, Kato M, Koton K, Sakamoto N, Shiota G, Nakamuta M, Nakashima M, Enjoji M. Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes. Int J Mol Med 2011, 27(5):619-624.
40. De Gottardi A, Spahr L, Ravier-Dall'Antonia F, Hadengue A. Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes. Liver Int 2010, 30(10):1482-1489. 10.1111/j.1478-3231.2010.02298.x, 20602678.
41. Westerbacka J, Kotronen A, Fielding BA, Wahren J, Hodson L, Pertila J, Perttilä J, Seppänen-Laakso T, Suortti T, Arola J, Hultcrantz R, Castillo S, Olkkonen VM, Frayn KN, Orešič M, Yki-Järvinen H. Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology 2010, 139(6):1961-1971. 10.1053/j.gastro.2010.06.064, 20600015.
42. Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, Nobili B, Pasquale G, Maione S, Adinolfi LE, Perrone L, Sagnelli E, Miraglia Del Giudice E, Rossi F. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014, 12:334-340. 10.1016/j.cgh.2013.05.008, 23707465.
43. Mendez-Sanchez N, Zamora-Valdés D, Pichardo-Bahena R, Barredo-Prieto B, Ponciano-Rodriguez G, Bermejo-Martínez L, Chavez-Tapia NC, Baptista-González HA, Uribe M. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int 2007, 27(2):215-219. 10.1111/j.1478-3231.2006.01401.x, 17311616.